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Abstract
Familial tumoral calcinosis (FTC)/hyperostosis-hyperphosphatemia syndrome (HHS) is a rare 
disorder caused by mutations in the genes encoding fibroblast growth factor-23 (FGF23), N-
acetylgalactosaminyltransferase 3 (GALNT3), or KLOTHO. The result is functional deficiency of, 
or resistance to, intact FGF23 (iFGF23), causing hyperphosphatemia, increased renal tubular 
reabsorption of phosphorus (TRP), elevated or inappropriately normal 1,25-dihydroxyvitamin D3 
(1,25D), ectopic calcifications and/or diaphyseal hyperostosis. Eight subjects with FTC/HHS were 
studied and treated. Clinical manifestations varied, even within families, ranging from 
asymptomatic to large, disabling calcifications. All subjects had hyperphosphatemia, increased 
TRP, and elevated or inappropriately normal 1,25D. C-terminal FGF23 was markedly elevated 
while iFGF23 was comparatively low, consistent with increased FGF23 cleavage. Radiographs 
ranged from diaphyseal hyperostosis to massive calcification. Two subjects with severe 
calcifications also had overwhelming systemic inflammation and elevated C-reactive protein 
(CRP). GALNT3 mutations were identified in 7 subjects; no causative mutation was found in the 
eighth. Biopsies from 4 subjects showed ectopic calcification and chronic inflammation, with 
areas of heterotopic ossification observed in 1 subject. Treatment with low phosphate diet, 
phosphate binders, and phosphaturia-inducing therapies was prescribed with variable response. 
One subject experienced complete resolution of a calcific mass after 13 months of medical 
treatment. In the 2 subjects with systemic inflammation, interleukin-1 (IL-1) antagonists 
significantly decreased CRP levels with resolution of calcinosis cutis and peri-lesional 
inflammation in one subject and improvement of overall well-being in both subjects. This cohort 
expands the phenotype and genotype of FTC/HHS and demonstrates the range of clinical 
manifestations despite similar biochemical profiles and genetic mutations. Overwhelming 
systemic inflammation has not been described previously in FTC/HHS; the response to IL-1 
antagonists suggests that anti-inflammatory drugs may be useful adjuvants. In addition, this is the 
first description of heterotopic ossification reported in FTC/HHS, possibly mediated by the 
adjacent inflammation.
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INTRODUCTION
Hyperphosphatemic familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome 
(FTC/HHS) (OMIM 211900) is a rare autosomal recessive disorder caused by mutations in 
the genes encoding one of the following: fibroblast growth factor 23 (FGF23, 12p13.3) (1), 
UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase-T3 (GalNAc-T3) (GALNT3, 
2q24-q31) (2), or Klotho (KL, 13q12) (3). FGF23 is produced by bone cells and is a primary 
regulator of phosphate homeostasis (4), with the intact hormone (iFGF23) acting via the 
fibroblast growth factor receptor 1 (FGFR1) along with its co-receptor Klotho to inhibit 
sodium phosphate co-transporter (NaPi-2a and-2c) and 25-hydroxyvitamin D 1-α-
hydroxylase expression. This leads to increased renal phosphate excretion and decreased 
serum 1,25-dihydroxyvitamin D3 (1,25D), lowering the blood phosphate level. Intact FGF23 
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undergoes post-translational O-linked glycosylation by GalNAc-T3 at a pro-protein 
convertase cleavage site, protecting iFGF23 from cleavage into inactive fragments (5). Thus, 
in the absence of O-linked glycosylation, iFGF23 is readily cleaved and inactivated.
The mutations causing FTC/HHS result in relative deficiency of, or resistance to, iFGF23, 
which leads to hyperphosphatemia, due to increased renal tubular reabsorption of phosphate 
(TRP), and elevated or inappropriately normal 1,25D production, which promotes 
gastrointestinal absorption of phosphorus and calcium. The net effect is an increase in the 
calcium × phosphate product. Affected individuals develop ectopic calcifications and/or 
diaphyseal hyperostosis, which may manifest clinically as diaphyseal pain of the long bones 
and is often erroneously diagnosed as osteomyelitis (6). Characteristic dental findings of 
FTC/HHS are often present including short bulbous teeth, shortened roots with dilacerations, 
thistle-shaped dental pulps, pulp chamber and root canal obliteration, and pulp stones (7–
10).
There is no standard treatment for this disease, and studies of the treatment of FTC/HHS do 
not exist aside from case reports or case series. Most reported therapies attempt to lower 
serum phosphate by instituting low phosphate diet, phosphate binders, or medications that 
promote renal excretion of phosphate (11–13). However, clinical response to these 
treatments is quite variable. Surgical debulking may be performed in subjects with 
functional impairment or severe pain, but is not routinely undertaken as calcinosis often 
recurs (14–16). In addition, post-surgical morbidity from attempted complete excision may 
occur. Here we present the clinical and molecular characterization of a cohort of subjects 
with FTC/HHS evaluated and treated with previously reported and novel therapies at the 
National Institutes of Health (NIH).
MATERIALS AND METHODS
Subjects
This study was approved by the Institutional Review Board of the National Institute of 
Dental and Craniofacial Research, NIH. Subjects were referred by their home physicians. 
Adult subjects or the parents of minors provided written consent to the study protocol; minor 
subjects > 7 years of age provided written assent. Clinical evaluations performed by 
subjects’ home physicians occurred prior to consenting to the NIH study, and subjects 
permitted use of this data for research purposes/publication upon signing informed consent. 
All subjects received a predefined set of evaluations that included detailed medical and 
family history, physical examination, dental examination, standard biochemical evaluation, 
detailed laboratory evaluation of calcium and phosphorus metabolism including 1,25D, 
intact parathyroid hormone (iPTH), TRP, iFGF23 and C-terminal FGF23 (CFGF23), genetic 
testing, and standard radiographs. The results of the standard evaluation were used to guide 
additional studies, e.g. computed tomography (CT) of symptomatic lesions, colonoscopy for 
evaluation of gastrointestinal luminal masses, etc. However, additional factors were 
considered in obtaining further studies, e.g. minimizing radiation exposure in children.
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Biochemical
Testing included routine blood and urine chemistries, complete blood count (CBC), 
erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), iPTH 
(electrochemiluminescence immunoassay on Roche Cobas e601 analyzer, NIH), and 1,25D 
(radioimmunoassay or liquid chromatography-tandem mass spectrometry, Mayo Medical 
Laboratories, Rochester, MN). iFGF23was measured by ELISA (Kainos Laboratories, 
Tokyo, Japan, or Immutopics International, San Clemente, CA), and CFGF23 was measured 
by ELISA (Immutopics International, San Clemente, CA). The iFGF23 assay measures only 
the intact protein while the CFGF23 assay reflects both the intact and C-terminal fragments.
Genetic analysis
For GALNT3 sequencing, genomic DNA was isolated from leukocytes using standard 
procedures. All coding exons and their adjacent intronic sequences in GALNT3 were 
amplified by PCR, using Multiplex PCR Kit (QIAGEN Inc., Valencia, CA). Approximately 
100 ng of purified PCR products were directly sequenced from PCR primers, using Big-Dye 
Terminator Cycle Sequencing Kit and the ABI PRISM 3100 Genetic Analyzer (Applied 
Biosystems, Foster City, CA)(14). DNA sequencing of FGF23 from whole blood was 
performed in a commercial laboratory (GeneDx, Gaithersburg, MD). No subjects were 
tested for mutations in KLOTHO.
Imaging
Tumoral calcinosis was assessed by conventional radiography and, in some, by CT. Two 
subjects had magnetic resonance imaging of tumoral calcinosis, and one underwent 
colonoscopy. Six subjects underwent dual energy x-ray absorptiometry (DXA) (Hologic 
QDR 4500; Hologic Inc, Waltham, MA) of the anteroposterior (AP) spine, total hip, and 1/3 
radius; sites with tumoral calcinosis were excluded. Height-adjusted Z-scores for bone 
mineral density (BMD) were calculated in subjects less than 20 years of age (17). Cardiac 
CT (Toshiba Aquillion ONE, Otawara, Japan) was performed in 5 subjects. Cardiac 
calcifications were quantified by using the Agatston calcium score (18). Dental radiographs 
were obtained in all subjects.
Treatment
All subjects received nutritional counseling and were prescribed a low phosphate diet 
targeting 400–900 mg/day, depending upon age. Prescription of phosphate-lowering 
medications was determined individually, depending on burden of calcinosis and response to 
previous therapies. Treatment of all subjects except FTC1 included sevelamer, a phosphate 
binder, prescribed with meals and snacks. All subjects but FTC3 and FTC5, who had no 
tumoral calcinosis, were additionally treated with acetazolamide and/or probenecid, both of 
which promote renal phosphate excretion. The acetazolamide was titrated up while closely 
monitoring the serum bicarbonate. The dose was held or decreased if the serum bicarbonate 
reached ≤ 16 mmol/L. The probenecid was increased until the blood uric acid level was 
suppressed or the maximum dose for age was reached. Aluminum hydroxide was added as 
an additional phosphate binder in 2 subjects, who had increased tumoral calcinosis burden 
with no change in blood phosphorus on sevelamer, acetazolamide and probenecid. Treatment 
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with nicotinamide was attempted during a hospitalization in 2 subjects to assess its effect on 
inducing phosphaturia but was not continued upon discharge, as it did not show additional 
benefits. Treatment efficacy was determined by changes in serum phosphorus, TRP, and 
tumoral calcinosis burden. One subject with severe functional impairment underwent 
surgical debulking of tumoral calcinosis at NIH while others had resections performed at 
outside institutions.
Two subjects with systemic inflammation were treated with either the monoclonal antibody 
to IL-1β, canakinumab, or the recombinant IL-1 receptor antagonist, anakinra. Doses were 
increased as tolerated in an effort to normalize CRP levels.
RESULTS
Clinical findings
Eight subjects (FTC1-FTC8) from six families with clinical and/or biochemical features 
consistent with FTC/HHS were examined (Table 1). On initial evaluation, 6 subjects had 
tumoral calcinosis on physical examination, typically periarticular, and of various sizes in 
multiple locations (Figure 1). Some lesions were painful and debilitating, reducing quality of 
life. FTC4 had a frozen left shoulder along with decreased range of motion of the left elbow 
due to tumoral calcinosis, which significantly affected self-care and activities of daily living, 
such as toileting and feeding. FTC3 and FTC5 are siblings of significantly affected subjects 
(FTC2 and FTC4, respectively), yet initially had no physical exam findings despite 
characteristic biochemical findings on screening laboratory evaluation (Table 1). FTC3 later 
developed tumoral calcinosis at the elbow noted at the three-year follow-up visit.
In addition to tumoral calcinosis, FTC2 had symptoms of intermittent fever as well as the 
onset of cutaneous calcinosis with inflammatory reaction (Figure 7B). FTC4 had no clinical 
manifestations of systemic inflammation other than chronic fatigue.
Biochemical findings
Median values are presented in text, individual values can be found in Table 1. All subjects 
were hyperphosphatemic with elevated TRP [96.5%] and TP/GFR [6.5 mg/dL (2.8 
mmol/L)](19). The 1,25D [62 pg/mL(161.2 pmol/L)] was frankly elevated or inappropriately 
normal for the degree of hyperphosphatemia. Serum calcium, creatinine, and alkaline 
phosphatase were normal. The calcium × phosphorus product [63.5 mg2/dL2 (5.12 mmol2/
L2)] was elevated in all but two patients, according to criteria defined by the National 
Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines (> 65 
mg2/dL2 for <12Y; >55 mg2/dL2 for >12Y) (20). iPTH levels [21 pg/mL (21 ng/L)] were in 
the lower 1/3 of normal in all subjects, except for FTC4 who had a low 25-OH-Vitamin D3 
level of 5 ng/mL (12.5 mmol/L). Consistent with increased FGF23 cleavage, iFGF23 (39 
pg/mL) ranged from low to just above normal for all subjects, which is inappropriate given 
the hyperphosphatemia, while the CFGF23 (1001 RU/mL) was significantly elevated. The 
ratio of total FGF23 (iFGF23 + CFGF23) to iFGF23 was much higher in subjects with 
FTC/HHS (35.3 ± 24.3, mean ± SD) compared to normal controls (0.99± 0.3) (21).
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Three subjects had biochemical evidence of systemic inflammation with significantly 
elevated CRP levels (max 81.8 mg/L in FTC2, 245.1 mg/L in FTC4, and 19.3 mg/L in 
FTC7; nl<4.99 mg/L) and ESR (max 90.9 in FTC2, 127 in FTC4, and 70 in FTC7; nl<25 
mm/hr). FTC2 and FTC4 also had anemia consistent with inflammation-mediated chronic 
disease and thrombocytosis (740K in FTC2 and 490K in FTC4; nl 199–367K). FTC4 had 
significantly elevated ferritin levels as high as 1137 mcg/L (2555 pmol/L; nl 30–400 mcg/L). 
FTC2 had leukocytosis with a white blood cell count as high as 219,000. FTC6 had anemia 
without inflammation, which was judged to be due to nutritional iron deficiency.
Genetic analyses
Five subjects in this cohort had compound heterozygous mutations in GALNT3, three of 
which were novel. FTC4 and FTC5, siblings from a consanguineous family, had novel 
homozygous GALNT3 mutations. No mutations in FGF23 or GALNT3 were identified in 
subject FTC7 and KLOTHO mutation testing was not performed as her biochemical profile 
(no evidence of iFGF23 resistance) was not consistent with mutations in KLOTHO (Table 
1).
Imaging findings
Calcinosis varied widely, ranging from none to involvement of multiple joints (Figure 2). 
FTC4 was the most significantly affected subject (Figure 2A, 2D, 2E) including substantial 
intraarticular infiltration and chondral damage of the left shoulder joint, resulting in 
ankylosis. FTC8 had growth plate obliteration by tumoral calcinosis with ulnar shortening. 
(Figure 2C).
BMD was within 2 SD of the mean for Z-score (adults and children) and T-score (adults 
only) for all subjects but one at the AP spine, total hip, and 1/3 radius. FTC4, who presented 
with severe, longstanding inflammation, had an AP spine BMD of 0.667 gm/cm2, T-score 
−3.9; total hip BMD of 0.551 gm/cm2, T-score −3.2; and 1/3 radius BMD of 0.612 gm/cm2, 
T-score −1.4.
FTC4 (32 years old) and FTC7 (56 years old) had cardiac calcifications on CT with 
Agatston coronary calcium scores of 105 (95th percentile for 45-year old ethnicity-matched 
men) (Figure 3B) and 157 (95th percentile for age and ethnicity-matched women), 
respectively. FTC4, who had longstanding untreated chronic inflammation, and FTC7, who 
had type 2 diabetes mellitus, hypertension, hyperlipidemia, and history of 60 pack-years 
smoking, both had increased risk factors for development of vascular calcification 
independently of FTC/HHS. No cardiac calcifications were seen in the other 3 subjects 
studied (ages 6–36 years).
Six subjects had characteristic dental findings (Figure 2B).
Histopathology
Specimens obtained following surgical resection of calcific tumors from the right chest and 
shoulder of FTC4 showed histologic evidence of calcification, as expected (Figure 4A). In 
addition to the calcification, heterotopic ossification was evident (Figure 4B). This existed 
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within the background of overwhelming chronic inflammation (Figure 4C). Tibia biopsy of 
FTC6 revealed hyperostosis with reactive woven bone which, over time, is converted to 
lamellar bone (Figure 5B&C).
Treatment
Subjects had variable responses to treatment with phosphate-lowering agents. For example, 
after 13 months on treatment, FTC6’s serum phosphorus and TRP decreased, and the 
tumoral calcinosis posterior to the left elbow completely resolved on radiograph (Figure 
6A). In contrast, despite optimizing medical therapy, there was no significant decrease in 
FTC4’s serum phosphorus or TRP (Figure 6B). Therefore, phosphate-lowering agents were 
discontinued in this subject prior to discharge. FTC4 underwent seven surgeries over 3 years 
in an effort to alleviate pain and improve ambulation.
Given the presumed increased IL-1 production by foamy macrophages seen on biopsies, 
inflammation in FTC4 was treated with a short course of anakinra, a recombinant IL-1 
receptor antagonist. Anakinra 100 mg subcutaneous daily was started initially and then 
increased to 100 mg twice daily, with a decrease in CRP levels from 176 mg/L to 26.6 mg/L 
over 16 days. On FTC4’s subsequent admission, anakinra was restarted at 100 mg daily and 
increased to 200 mg daily; CRP levels declined significantly but did not normalize (Fig 7F). 
Treatment was continued for 4 months but then discontinued as the subject was unable to 
obtain the medication. Off therapy, symptoms returned and biochemical markers of 
inflammation increased. FTC2’s inflammatory response was initially treated with oral 
prednisone, topical steroids, and ibuprofen, without improvement. Therapy was changed to 
subcutaneous canakinumab, a monoclonal interleukin-1β (IL-1 β) antibody, at a starting 
dose of 2 mg/kg every 8 weeks (50 mg), and increased to 3 mg/kg every 8 weeks (100 mg), 
with normalization of CRP levels (Fig 7A). Because of a needle phobia, canakinumab was 
prescribed every eight weeks instead of once or twice daily injections of anakinra. The 
subject has continued on therapy for the past 2.5 years. Both subjects reported more energy, 
improved appetite, and an overall improved sense of well-being while on IL-1 blockade. Of 
note, FTC2 reported greater adherence to phosphate lowering medications during this time, 
which likely contributed to her improvement in symptoms.
DISCUSSION
Hyperphosphatemia due to increased renal TRP and elevated or inappropriately normal 
1,25D are the biochemical hallmarks of FTC/HHS. When due to mutations in FGF23 or 
GALNT3, CFGF23 is significantly elevated with a low or normal iFGF23, indicating 
increased processing of the biologically active iFGF23. Despite the low or normal iFGF23, 
iFGF23 action appears blunted, suggesting that CFGF23 may competitively inhibit iFGF23 
binding to FGFR1(22). Thus, FTC/HHS is the biochemical mirror of iFGF23 excess 
conditions, such as tumor-induced osteomalacia (23), X-linked hypophosphatemic 
rickets(24), and autosomal dominant hypophosphatemia(25).
The reported clinical spectrum of FTC/HHS is variable ranging from isolated eyelid 
calcifications to massive periarticular calcifications; this holds true in our NIH cohort. Most 
subjects had onset of tumoral calcinosis in childhood; however, FTC7 was unique with the 
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development of calcifications at 45 years. Because of the late onset of tumoral calcinosis, 
FTC7 underwent an extensive evaluation for possible causes of ectopic calcifications 
including the following rheumatologic diagnoses: dermatomyositis, scleroderma, lupus, 
mixed connective tissue disease, and CREST syndrome; all of which were excluded. 
However, other theoretical environmental, acquired, or autoimmune etiologies could not be 
excluded. Two subjects were asymptomatic at initial evaluation despite biochemical findings 
similar to their respective siblings who were severely affected at an early age. Variable 
clinical presentation among family members with the same mutation suggests the role of 
genetic or environmental modifiers (i.e., trauma) in the clinical presentation. Due to the 
heterogeneity of this disease, systematic phenotyping and indication-directed therapy, as 
outlined above, is recommended.
While the distribution of calcifications has typically been reported in the skin or 
subcutaneous tissue, usually in periarticular locations with no joint or bony involvement, 
FTC4 had complete destruction of the left shoulder joint and FTC8 had destruction of the 
ulnar growth plate. Thus, extension into bones and/or joints is a previously unreported 
complication with the potential to severely affect quality of life and activities of daily living. 
In addition, we identified large calcifications in the submucosal lining of the large intestine, 
another novel location.
The greatest potential risk associated with FTC/HHS may be vascular calcification (26, 27). 
Two of the five subjects evaluated had coronary calcifications, with Agatston scores above 
the 95th percentile. As the two affected had other risk factors for cardiac calcification, the 
lack of cardiac calcification in other subjects may be a function of young age and other 
factors. Therefore, the risk of cardiac calcification associated with FTC/HHS, and its 
sequelae are not clear at this time.
In an effort to reduce the calcium × phosphate product, subjects were instructed to follow a 
low-phosphate diet. Given the ubiquity of phosphate in foods, adherence was variable. 
Symptomatic subjects were treated with sevelamer, a non-calcium based phosphate binder 
(28), to reduce intestinal absorption. Aluminum hydroxide was added as an additional 
phosphate binder in 2 subjects, as the potential for aluminum toxicity is low when renal 
function is normal. Most subjects were treated with acetazolamide, a carbonic anhydrase 
inhibitor, and probenecid, a uricosuric agent, both of which increase renal phosphate 
excretion. While the exact mechanism of probenecid is unknown, acetazolamide, induces a 
proximal renal tubular acidosis resulting in phosphaturia (29). Therefore, monitoring of 
serum bicarbonate to avoid significant acidosis is important. Recent work in the Klotho-
deficient mouse, a model for FTC, suggests that acetazolamide may also prevent tissue 
calcification by inducing acidosis (30). In addition to its uricosuric properties, probenecid 
also prolongs the half-life of antibiotics. Thus, one should be cautious when prescribing 
other drugs such as penicillin, cephalosporins, and trimethoprim-sulfamethoxazole, which 
when used in combination with probenecid, can result in antibiotic toxicity. Surgery was 
avoided, except for severely painful or disabling lesions.
The response to medical therapy was variable amongst subjects, some of which could be 
attributed to nonadherence with the difficult dosing regimen. Therapy with acetazolamide 
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and phosphate binders has previously been reported to result in complete resolution of 
tumoral calcinosis in two cases (11, 31) and either a decrease in size, reduced progression, 
or absence of new lesions (12, 32). While improvement of ectopic calcifications in 
rheumatologic disorders treated with probenecid has been reported (33), this is the first 
report of successful treatment of tumoral calcinosis in FTC/HHS with probenecid. As all of 
our subjects receiving probenecid were also on sevelamer and acetazolamide, it is not known 
if the effect was additive or coincidental. Further work is necessary to determine the benefit 
of probenecid in the treatment of FTC/HHS, if any, but it serves as another phosphaturic 
agent that may be utilized.
Two previously reported subjects had evidence of increased inflammation (31, 34). In our 
cohort, three of the eight subjects had overwhelming systemic inflammation. Inflammation 
correlated with severity of clinical disease, but there was no correlation with TRP. IL-1 
blockade decreased inflammatory markers, reduced tumor burden, and led to subjective 
improvement in energy level, appetite, and overall well-being in two subjects. While the role 
of inflammation in the pathogenesis of FTC/HHS remains to be elucidated, treatment of 
inflammation may be important adjuvant therapy.
Histologic analyses showed ectopic calcification in a background of chronic inflammation 
with multiple foamy macrophages. Others have shown the presence of macrophages and 
multinucleated giant cells on histology from biopsies of tumoral calcinosis (12, 35), and 
older literature describes the presence of woven bone (36). However, there are no reports of 
heterotopic ossification within tumoral calcinosis lesions with mature remodeling of lamellar 
bone and the presence of reversal lines as seen in our cohort. We hypothesize that the 
chronic inflammation may contribute to recruitment/development of local progenitor cells 
with osteogenic potential to form ectopic bone, possibly similar to the mechanism of 
heterotopic ossification in fibrodysplasia ossificans progressiva (37).
This study is limited by the small number of study subjects and the individualized treatment 
regimens. However, this is the largest reported cohort of subjects with FTC/HHS from 
different families with known causative mutations in 7 subjects. Further genetic evaluation is 
ongoing in the subject in whom a causative mutation was not identified. While a 
randomized, placebo-controlled treatment trial is ideal, it is not feasible given the disorder’s 
rarity. In addition, interpreting the response to therapy is difficult in cases of poor adherence 
and lack of long-term follow-up, which occurred with some subjects. Finally, referral bias 
may also affect our findings. As a tertiary referral center, these subjects may be more 
severely affected, thus diminishing potential generalizability of the findings.
This cohort broadens the phenotype and genotype of FTC/HHS and provides insight into the 
efficacy of a combined treatment regimen of phosphate binders and phosphaturic agents. For 
the first time, we present evidence of heterotopic ossification and overwhelming systemic 
inflammation in subjects with FTC/HHS and improvement of these symptoms with anti-
inflammatory medications. These data suggest that inflammation may play a role in the 
pathogenesis of this disorder and that treatment of the inflammation may be important for 
disease management.
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Figure 1. Clinical manifestations of the FTC/HHS cohort
(A) Massive calcifications surrounding the right shoulder and chest in FTC4. (B&C) 
Tumoral calcinosis of the elbow (38), which later ulcerated and drained thick, white “milk of 
calcium” in FTC2. (D) Calcifications of the right palmar surface, the dominant hand, in 
FTC7 who was an avid bowler. (E) Tumoral calcinosis of the elbow and wrist in FTC8.
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Figure 2. Imaging of FTC/HHS cohort
(A) CT showing calcifications in FTC4 including shoulder and hip soft tissue calcifications 
(white arrows), aortic calcification (dashed arrow), papillary muscle calcification (black 
arrow), and submucosal gut calcifications (asterisks). (B) Panoramic dental radiograph 
showing short, bulbous roots (solid arrows) with obliteration of dental pulp (asterisks). Inset 
- thistle-shaped pulp chambers and a pulp stone (dashed arrow) in FTC5. (C) Radiograph 
showing tumoral calcinosis of elbow (solid arrow) and ulna with growth plate invasion and 
destruction in FTC8 (dashed arrow). (D) Submucosal gut calcification on colonoscopy in 
FTC4. (E) CT showing large cystic masses in the chest wall with fluid levels containing 
“milk of calcium” in FTC4 (arrow). (F) CT 3-D reconstruction demonstrating extensive 
calcifications in bilateral hips and scattered calcifications throughout the chest in FTC7.
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Figure 3. Cardiac CT angiography in FTC4
(A) Calcification of left anterior descending (LAD) artery on original scan (arrow) (Agatston 
score = 6). (B) Increased calcification in LAD 3 years later (arrow) (Agatston score = 105; 
95th percentile). (C) Calcification of posterior medial papillary muscle (arrow) (Agatston 
score = 167), which remained relatively stable over 3y.
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Figure 4. Histology (H&E) and electron micrograph (EM) of tumoral calcinosis resected from 
FTC4
(A) Subcutaneous ectopic calcification (arrows). (B) Heterotopic ossification with 
osteoblasts laying down new bone (black arrows) as well as reversal lines (white arrows) 
indicating active bone remodeling. (C) Chronic inflammation with foamy macrophages 
(arrows) associated with heterotopic ossification (asterisks). (D) EM showing macrophages 
with stellate needle-like inclusions consistent with calcium deposition (arrows).
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Figure 5. Radiographic and histopathologic features of hyperostosis
(A) Radiograph tibias/fibulas showing hyperostosis with hypermineralization of the cortical 
bone (dashed arrow) and patchy sclerosis (solid arrows) of the medullary cavities in FTC2. 
(B) H&E (100×) stained sections from tibia biopsy of FTC6 show periosteal bone with a 
central core of woven bone (asterisks) being replaced by lamellar bone (arrows). (C) 
Goldner trichrome (40×) stained undecalcified sections show woven bone in red and 
lamellar bone in light blue.
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Figure 6. Response to phosphate-lowering therapies in two subjects
(A) After 13 months of low-phosphate diet, sevelamer, acetazolamide, and probenecid, 
FTC6’s serum phosphorus and TRP decreased, and (B) the tumoral calcinosis posterior to 
the elbow completely resolved (arrow). (C) Treatment with sevelamer, probenecid, 
acetazolamide, aluminum hydroxide, and nicotinamide in a stepwise approach along with a 
low phosphate diet during an inpatient hospitalization. Despite optimizing medical therapy, 
there was no significant decrease in FTC4’s serum phosphorus or TRP; to the contrary, the 
serum phosphorus appeared higher while on medical therapy. *Normal range for TRP is 85–
95% when blood phosphorus is in the normal range.
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Figure 7. Treatment of systemic inflammation in FTC2 and FTC4
(A) In FTC2, C-reactive protein (CRP) levels normalized and (B&C) painful, erythematous, 
calcinosis cutis (38) resolved on canakinumab therapy. (D) Increased edema surrounding 
right hip tumoral calcinosis on pelvis MRI (STIR). Accounting for differences in technique 
(3.0 T (D) versus 1.5 T (E)), (E) there was also marked improvement in peri-lesional edema 
following treatment with canakinumab in FTC2. (F) Anakinra decreased CRP levels in 
FTC4. Rebound CRP elevation observed on Day 25 after a missed dose.
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, G
A
LN
T3
: N
-
ac
et
yl
ga
la
ct
os
am
in
yl
tra
ns
fe
ra
se
 3
. T
o
 c
o
nv
er
t p
ho
sp
ho
ru
s t
o 
m
m
ol
/L
, m
ul
tip
ly
 b
y 
0.
32
3.
 T
o
 
co
nv
er
t c
al
ci
um
 to
 m
m
ol
/L
, m
ul
tip
ly
 b
y 
0.
25
. T
o
 c
o
nv
er
t 1
,2
5-
O
H
 V
ita
m
in
 D
3 
to
 p
m
ol
/L
, m
ul
tip
ly
 b
y 
2.
6.
 F
o
r 
PT
H
 p
g/
m
L 
= 
ng
/L
.
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